Solventum Corporation $SOLV Shares Acquired by LSV Asset Management

LSV Asset Management grew its holdings in Solventum Corporation (NYSE:SOLV) by 143.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,561 shares of the company’s stock after acquiring an additional 4,461 shares during the period. LSV Asset Management’s holdings in Solventum were worth $573,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Solventum by 0.7% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after purchasing an additional 140 shares during the period. Tradition Wealth Management LLC grew its position in Solventum by 1.6% during the 1st quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock worth $671,000 after purchasing an additional 143 shares during the period. Applied Finance Capital Management LLC raised its stake in shares of Solventum by 3.8% during the 2nd quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock valued at $336,000 after buying an additional 162 shares during the last quarter. SouthState Corp raised its stake in shares of Solventum by 31.9% during the 1st quarter. SouthState Corp now owns 699 shares of the company’s stock valued at $53,000 after buying an additional 169 shares during the last quarter. Finally, HB Wealth Management LLC lifted its holdings in shares of Solventum by 5.6% in the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock valued at $263,000 after buying an additional 185 shares during the period.

Solventum Trading Up 4.3%

Shares of SOLV stock opened at $82.93 on Friday. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $85.92. The company has a market cap of $14.38 billion, a price-to-earnings ratio of 9.55, a PEG ratio of 8.39 and a beta of 0.48. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The stock has a 50 day simple moving average of $72.68 and a 200-day simple moving average of $73.08.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its board has authorized a stock repurchase program on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several research firms recently commented on SOLV. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Piper Sandler lifted their target price on shares of Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wells Fargo & Company boosted their target price on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Finally, UBS Group reissued a “neutral” rating on shares of Solventum in a report on Friday. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $85.56.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.